Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population
- PMID: 11117911
- DOI: 10.1016/S0140-6736(00)03231-1
Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population
Abstract
Background: One of the most critical questions in immunosurveillance is whether differences between individuals with regards to natural immunological host defence can predict future development of cancer. Although this question has so far remained open, there are clear indications of significant roles of several naturally cytotoxic lymphocytes in preventing the development of cancer. We began a prospective cohort study among a Japanese general population in 1986, using various immunological and biochemical markers.
Methods: Natural cytotoxic activity of peripheral-blood mononuclear cells was assessed by isotope-release assay in 3625 residents of a Japanese population mostly older than 40 years of age, between 1986 and 1990. Immunological and biochemical markers were also measured, and participants were given a questionnaire on lifestyle. We did an 11-year follow-up survey of the cohort members looking at cancer incidence and death from all causes, and analysed the association between cytotoxic activity of peripheral-blood lymphocytes assessed at baseline and cancer incidence found in the subsequent follow-up.
Findings: 154 cancer cases were used in the analysis. When we categorised the cytotoxic activity of peripheral-blood lymphocytes by tertiles, age-adjusted relative risk of cancer incidence (all sites) was 0.72 (95% CI 0.45-1.16) for men with high cytotoxic activity, and 0.62 (0.38-1.03) for men with medium cytotoxic activity, taking the risk of those with low cytotoxic activity as reference. For women with high cytotoxic activity relative risk was 0.52 (0.28-0.95), and for those with medium cytotoxic activity 0.56 (0.31-1.01). For both sexes with high and medium cytotoxic activity risk was 0.63 (0.43-0.92) and 0.59 (0.40-0.87), respectively.
Interpretation: Our results indicate that medium and high cytotoxic activity of peripheral-blood lymphocytes is associated with reduced cancer risk, whereas low activity is associated with increased cancer risk suggesting a role for natural immunological host defence mechanisms against cancer.
Similar articles
-
Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance.Cancer Res. 2006 Jan 1;66(1):563-70. doi: 10.1158/0008-5472.CAN-05-2776. Cancer Res. 2006. PMID: 16397273
-
Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.J Urol. 1996 Mar;155(3):888-92; discussion 892-4. J Urol. 1996. PMID: 8583600
-
Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes.Cancer Res. 1987 Jan 1;47(1):173-7. Cancer Res. 1987. PMID: 3491673
-
Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.Res Rep Health Eff Inst. 2009 Mar;(139):5-71; discussion 73-89. Res Rep Health Eff Inst. 2009. PMID: 19554969
-
Perspectives on cancer immuno-epidemiology.Cancer Sci. 2004 Dec;95(12):921-9. doi: 10.1111/j.1349-7006.2004.tb03178.x. Cancer Sci. 2004. PMID: 15596039 Free PMC article. Review.
Cited by
-
Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.PLoS One. 2013;8(2):e55945. doi: 10.1371/journal.pone.0055945. Epub 2013 Feb 8. PLoS One. 2013. PMID: 23409093 Free PMC article.
-
Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.Front Immunol. 2020 Aug 14;11:1771. doi: 10.3389/fimmu.2020.01771. eCollection 2020. Front Immunol. 2020. PMID: 32922390 Free PMC article.
-
Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system.Front Immunol. 2023 Nov 23;14:1294434. doi: 10.3389/fimmu.2023.1294434. eCollection 2023. Front Immunol. 2023. PMID: 38077402 Free PMC article. Review.
-
Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial.PLoS One. 2015 Jun 10;10(6):e0123416. doi: 10.1371/journal.pone.0123416. eCollection 2015. PLoS One. 2015. PMID: 26062124 Free PMC article. Clinical Trial.
-
Prednisolone and enoxaparin (clexane) therapy ('the Bondi protocol') for repeated IVF failure.Am J Reprod Immunol. 2022 Nov;88(5):e13616. doi: 10.1111/aji.13616. Epub 2022 Sep 11. Am J Reprod Immunol. 2022. PMID: 36067527 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical